- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00048035
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
26 de octubre de 2016 actualizado por: Hoffmann-La Roche
An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in Hemodialysis Patients With Chronic Renal Anemia.
This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin.
The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
91
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35211
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
-
-
Illinois
-
Maywood, Illinois, Estados Unidos, 60153
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202-1718
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48236
-
Detroit, Michigan, Estados Unidos, 48202-2689
-
-
Minnesota
-
Brooklyn Center, Minnesota, Estados Unidos, 55430
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
-
-
New Jersey
-
Paterson, New Jersey, Estados Unidos, 07503
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11203
-
Mineola, New York, Estados Unidos, 11501
-
New York, New York, Estados Unidos, 10128
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- adult patients >=18 years of age;
- chronic renal anemia;
- on hemodialysis therapy for at least 3 months;
- receiving iv epoetin alfa during the 2 weeks prior to the run-in period.
Exclusion Criteria:
- women who are pregnant, breastfeeding or using unreliable birth control methods;
- use of any investigational drug within 30 days of the run-in phase, or during the run-in or study treatment period.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Cohort 1 (RO0503821 [0.25/150 1x/week])
Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
Experimental: Cohort 2 (RO0503821 [0.25/150 1x/2week])
Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
Experimental: Cohort 3 (RO0503821 [0.4/150 1x/week])
Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
Experimental: Cohort 4 (RO0503821 [0.4/150 1x/2week])
Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
Experimental: Cohort 5 (RO0503821 [0.6/150 1x/week])
Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
Experimental: Cohort 6 (RO0503821 [0.6/150 1x/2week])
Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks.
After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
|
Differing doses and frequencies of iv administration
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen
Periodo de tiempo: From Baseline (Day -28 to Day 1) to EOIT (Week 19)
|
Median change from Baseline in hemoglobin (Hb) levels to end of initial treatment (EOIT) under constant dosing regimen was reported.
For ease of interpretation, all individual slope values were multiplied by 42 to give an estimate of change in Hb values over six weeks.
Baseline (Day -28 to Day 1) Hb values was calculated as the mean of the screening assessment (SA) and run-in period (Week -2 and Week -1).
For all participants, an EOIT value was calculated as the last observed Hb value before a dose change or blood transfusion.
For participants without any dose adjustments or blood transfusion, the EOIT value was identical to the Week 19 value.
|
From Baseline (Day -28 to Day 1) to EOIT (Week 19)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Median Change From Baseline in Hematocrit Levels to End of Initial Treatment Under Constant Dosing Regimen
Periodo de tiempo: From Baseline (Day -28 to Day 1) to EOIT (Week 19)
|
Median change from Baseline in hematocrit (Hct) levels to end of initial treatment under constant dosing regimen was reported.
Baseline (Day -28 to Day 1) Hct values was calculated as the mean of the SA and run-in period (Weeks -2 and -1).
For all participants, an EOIT value was calculated as the last observed Hct value before a dose change or blood transfusion.
For participants without any dose adjustments or blood transfusion, the EOIT value was identical to the Week 19 value.
|
From Baseline (Day -28 to Day 1) to EOIT (Week 19)
|
Number of Participants With Any Adverse Events, Any Serious Adverse Events, And Deaths
Periodo de tiempo: Up to Week 126
|
An Adverse Events (AEs) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Serious Adverse Events (SAEs) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes.
).
The study design tested 3 different starting dose conversion factors at 3 different dosing schedules during the core study period.
As study drug doses can be modified continually over time all results for the two long term safety periods were displayed by dose schedule group only.
|
Up to Week 126
|
Number of Participants With Marked Laboratory Abnormalities
Periodo de tiempo: Up to Week 126
|
Marked abnormality was defined as above and/or below a value which was considered to be potentially clinically relevant.
The number of participants with marked lab abnormality across treatment groups were reported and presented.
Marked laboratory abnormalities were analyzed according to the Roche specified limits for the following reference range: White blood cells (WBC) (3.0- 18.0 10^9/L), Platelets (100 - 550 10^9/L), Alanine aminotransferase (ALAT) [0 110 units per litre (U/L)], Alkaline Phosphatase (ALP) (0 - 220 U/L), Aspartate aminotransferase (ASAT) (0 - 80 U/L), Albumin >= 30 g/L, Phosphate [0.75 - 1.60 millimoles per liter (mmol/L)], Potassium (2.9 - 5.8 mmol/L), Glucose (2.80 - 11.10 mmol/L).
|
Up to Week 126
|
Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Before and After Dialysis
Periodo de tiempo: From Baseline (Day -28 to Day 1) to Week 126
|
Mean Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) is calculated as the end of treatment values minus the Baseline value.
Baseline (Day -28 to Day 1) values were calculated as the mean of the screening assessment (SA) and run-in period (Week -2 and Week -1).
|
From Baseline (Day -28 to Day 1) to Week 126
|
Mean Change in Pulse Rate
Periodo de tiempo: Up to Week 126
|
Participants pulse rates in beats per minute (BpM) were analyzed at sitting position using descriptive statistical methods (ie, means, standard deviations and percentiles).
The changes in pulse rate throughout the study were analysed at each study visit and mean change is reported.
|
Up to Week 126
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de marzo de 2002
Finalización primaria (Actual)
1 de junio de 2005
Finalización del estudio (Actual)
1 de junio de 2005
Fechas de registro del estudio
Enviado por primera vez
24 de octubre de 2002
Primero enviado que cumplió con los criterios de control de calidad
24 de octubre de 2002
Publicado por primera vez (Estimar)
25 de octubre de 2002
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
20 de diciembre de 2016
Última actualización enviada que cumplió con los criterios de control de calidad
26 de octubre de 2016
Última verificación
1 de octubre de 2016
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- BA16285
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .